Diversity of the Circulating Tumor Markers: Perspectives of a Multimodal Liquid Biopsy
- 1 November 2024
- journal article
- review article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 89 (11) , 1985-1997
Abstract
Over the past decade, liquid biopsy (LB) has become a routine diagnostic test essential for the treatment of malignant tumors of various localizations. Its capabilities include early diagnosis, molecular genotyping, prognosis, prediction, and monitoring of tumor response. Typically, liquid biopsy involves the extraction of a single type of tumor-derived molecules or cellular elements from blood and subsequent molecular analysis. These elements may include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating tumor RNA (ctRNA), or contents of extracellular vesicles (exosomes). Despite the technical sophistication of molecular analysis methods for circulating biomarkers, this diagnostic approach has limited relevance. In a significant proportion of cancer patients (ranging from 10 to 50%, depending on the tumor type), none of these analytes can be detected and analyzed, even in the presence of large, progressing neoplastic foci in the body. It seems reasonable to suggest that heterogeneous fractions of the circulating tumor-specific biomarkers complement each other, thus simultaneous analysis of several fractions will not only increase sensitivity of the method but also more accurately characterize and predict the clinical situation. This review examines the possibilities and advantages of applying a combined multiparametric approach to liquid biopsy, which involves testing multiple circulating analytes in a single blood sample.Keywords
This publication has 100 references indexed in Scilit:
- Liquid biopsy for breast cancer and other solid tumors: a review of recent advancesBreast Cancer, 2024
- Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer CohortJAMA Network Open, 2024
- Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyAnnals of Oncology, 2022
- Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancerInternational Journal of Clinical Oncology, 2022
- Cancer diagnostics based on plasma protein biomarkers: hard times but great expectationsMolecular Oncology, 2020
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studiesInternational Journal of Cancer, 2020
- Pre‐analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patientsMolecular Oncology, 2020
- Enrichment and Analysis of ctDNA2019
- Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects2015
- Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapyJournal of Cellular Physiology, 2011